home / stock / imuc / imuc quote
Last: | $0.1979 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.1979 |
High: | $0 |
Low: | $0 |
Volume: | 12 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.1979 | $0 | $0.1979 | $0 | $0 | 12 | 04-24-2024 |
$0.1979 | $0 | $0.1979 | $0 | $0 | 18 | 04-23-2024 |
$0.1979 | $0.16499 | $0.1979 | $0.1979 | $0.16499 | 1,707 | 04-22-2024 |
$0.1979 | $0.1979 | $0.1979 | $0.1979 | $0.1979 | 212 | 04-19-2024 |
$0.17645 | $0.1979 | $0.17645 | $0.1979 | $0.17645 | 297 | 04-18-2024 |
$0.15 | $0.16 | $0.15 | $0.1979 | $0.15 | 1,308 | 04-17-2024 |
$0.1979 | $0.1979 | $0.1979 | $0.1979 | $0.1979 | 100 | 04-16-2024 |
$0.1421 | $0 | $0.1421 | $0 | $0 | 84 | 04-15-2024 |
$0.1421 | $0 | $0.1421 | $0 | $0 | 76 | 04-12-2024 |
$0.1421 | $0.2 | $0.1421 | $0.2 | $0.1421 | 332 | 04-11-2024 |
$0.1311 | $0.2 | $0.1311 | $0.2 | $0.1311 | 5,809 | 04-10-2024 |
$0.15177 | $0.2189 | $0.15177 | $0.2189 | $0.15177 | 2,600 | 04-09-2024 |
$0.2189 | $0.1365 | $0.2189 | $0.219 | $0.1311 | 9,402 | 04-08-2024 |
$0.11 | $0.22 | $0.11 | $0.22 | $0.11 | 6,915 | 04-05-2024 |
$0.198 | $0 | $0.198 | $0 | $0 | 15 | 04-04-2024 |
$0.198 | $0.198 | $0.198 | $0.198 | $0.198 | 110 | 04-03-2024 |
$0.19 | $0.19 | $0.19 | $0.19 | $0.19 | 200 | 04-02-2024 |
$0.152 | $0.171 | $0.152 | $0.248 | $0.152 | 15,837 | 04-01-2024 |
$0.152 | $0.268 | $0.152 | $0.268 | $0.152 | 21,718 | 03-29-2024 |
$0.152 | $0.268 | $0.152 | $0.268 | $0.152 | 21,718 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
ImmunoCellular Therapeutics Ltd. Company Name:
IMUC Stock Symbol:
OTCMKTS Market:
EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613 PR Newswire MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug...
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil PR Newswire Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , ...
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology indu...